Nesrine Kallel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nesrine Kallel has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Ilhem Yangui
Department of Pneumology HEDI CHAKER Hospital, University of Sfax Sfax Tunisia
4 shared publications- Rahma Gargouri
Faculty of Medicine of Sfax, University of Sfax, Sfax, Tunisia
3 shared publications - Rim Khemakhem
Department of Pneumology, Hedi Chaker Hospital, University of Sfax, Tunisia
3 shared publications Sameh Msaad
Department of Pneumology, Hedi Chaker University Hospital Sfax Tunisia
3 shared publicationsSamy Kammoun
Department of Pneumology HEDI CHAKER Hospital, University of Sfax Sfax Tunisia
3 shared publications- Afef Khanfir
Department of Medical Oncology, Habib Bourguiba Hospital, Sfax 3002, Tunisia
2 shared publications
Latest Publications
- 20 January 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 303
EGFR mutation spectrum and clinical correlations in Tunisian Non-Small cell lung cancer patients
- 20 January 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 303
EGFR mutation spectrum and clinical correlations in Tunisian Non-Small cell lung cancer patients
- 31 December 2022
- Published by Elsevier in Sleep Medicine
- Vol. 102, 90-104
Sleep habits and quality among war and conflict-affected Palestinian adults in the Gaza strip
- 31 December 2022
- Published by Elsevier in Sleep Medicine
- Vol. 102, 90-104
Sleep habits and quality among war and conflict-affected Palestinian adults in the Gaza strip
- Open Access
Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma
Objectives: Several new cancer therapies targeting signaling pathways involved in the growth and progression of cancer cells were developed as personalized medicine. Our study aimed to identify epidermal growth factor receptor (EGFR) mutations for TKI treatment in non-small-cell lung cancer (NSCLC) Tunisian patients. Methods: Analysis of the TKI sensitivity mutations in exons 18 to 21 of the EGFR gene and exon 15 of the B-raf gene was performed in 79 formalin fixed-paraffin embedded (FFPE) NSCLC samples using pyrosequencing. Results: EGFR mutations were detected in 34 cases among 79 (43%), with the predominance of the L861Q in exon 21 found in 35.3% of the cases (12 out of 34). Deletions in exon 19 were found in 8 cases (23.5%), and only one young male patient had the T790M mutation. Three patients harbored composite EGFR mutations (p.E746_A750del/p.L861R, p.E746_S752>V/p.S768I, and p.G719A/p.L861Q). Furthermore, the EGFR mutated status was significantly more frequent in female patients (p = 0.019), in non-smoker patients (p = 0.008), and in patients with metastasis (p = 0.044). Moreover, the B-raf V600E was identified in 5 EGFR negative patients among 39 analyzed samples (13.15%). Conclusion: The p.L861Q localized in exon 21 of the EGFR gene was the most common mutation identified in our patients (35.3%), whereas the “classic” EGFR mutations such as Del19 and p.L858R were found in 23.5% and 11.7% of the cases, respectively. Interestingly, most of p.L861X mutation-carrying patients showed good response to TKI treatment. Altogether, our findings suggest a particular distribution of the EGFR-TKIs sensitivity mutations in Tunisian NSCLC patients.
Open AccessPredominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma
Objectives: Several new cancer therapies targeting signaling pathways involved in the growth and progression of cancer cells were developed as personalized medicine. Our study aimed to identify epidermal growth factor receptor (EGFR) mutations for TKI treatment in non-small-cell lung cancer (NSCLC) Tunisian patients. Methods: Analysis of the TKI sensitivity mutations in exons 18 to 21 of the EGFR gene and exon 15 of the B-raf gene was performed in 79 formalin fixed-paraffin embedded (FFPE) NSCLC samples using pyrosequencing. Results: EGFR mutations were detected in 34 cases among 79 (43%), with the predominance of the L861Q in exon 21 found in 35.3% of the cases (12 out of 34). Deletions in exon 19 were found in 8 cases (23.5%), and only one young male patient had the T790M mutation. Three patients harbored composite EGFR mutations (p.E746_A750del/p.L861R, p.E746_S752>V/p.S768I, and p.G719A/p.L861Q). Furthermore, the EGFR mutated status was significantly more frequent in female patients (p = 0.019), in non-smoker patients (p = 0.008), and in patients with metastasis (p = 0.044). Moreover, the B-raf V600E was identified in 5 EGFR negative patients among 39 analyzed samples (13.15%). Conclusion: The p.L861Q localized in exon 21 of the EGFR gene was the most common mutation identified in our patients (35.3%), whereas the “classic” EGFR mutations such as Del19 and p.L858R were found in 23.5% and 11.7% of the cases, respectively. Interestingly, most of p.L861X mutation-carrying patients showed good response to TKI treatment. Altogether, our findings suggest a particular distribution of the EGFR-TKIs sensitivity mutations in Tunisian NSCLC patients.
- Open Access
- 8 August 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (8)
Coronavirus disease 19 (COVID‐19) and Cerebral venous sinus thrombosis (CVST): A case series and review of the literature
A large proportion of patients with coronavirus disease 19 (COVID‐19) suffer from excessive coagulation activation and coagulopathy which predisposes them to a wide spectrum of thrombotic events including in situ pulmonary thrombosis, deep‐vein thrombosis, and associated pulmonary embolism, as well as arterial thrombotic events. Cerebral venous sinus thrombosis (CVST) have also been reported but in a very small number of cases. This report aims to increase awareness about CVST as a potential neurological thromboembolic complication in patients with coronavirus disease. We report three COVID‐19 patients presenting with CVTS. We also review all previously described cases and present an overview of their demographic, clinical, and diagnostic data. We describe three patients with concomitant coronavirus disease and CVST among 1000 hospitalized COVID‐19 patients (2 males, 1female, and mean age of 37 years). One patient was previously healthy, while the two others had a history of chronic anemia and ulcerative colitis, respectively. CVST symptoms including seizure in two patients and headache in one patient occurred day to weeks after the onset of COVID‐19 symptoms. Three months of anticoagulant therapy was given for all three patients with favorable outcomes. No neurological sequelae and no recurrence occurred within 6 months after hospital discharge. Our search identified 33 cases of COVID‐19 complicated by CVST. The mean age was 45.3 years, there was a slight male predominance (60%), and more than half of cases were diagnosed in previously healthy individuals. All cases of CVT were clinically symptomatic and were observed in patients with a different spectrum of coronavirus disease severity. Headache was the most common complaint, reported by just less than half of patients. There was a high mortality rate (30.3%). CVT is a very rare, but potentially life‐threatening complication in patients with COVID‐19. It's mainly reported in relatively young individuals with no or little comorbid disease and can occur even in patients who do not display severe respiratory symptoms. Atypical clinical presentations may pose a challenge to the early diagnosis and treatment. High suspicion is necessary as early diagnosis and prompt treatment with anticoagulation in all patients with COVID‐19 and CVT could contain the mortality rate and improve neurological outcomes in these patients.
- 8 August 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (8)
Open AccessCoronavirus disease 19 (COVID‐19) and Cerebral venous sinus thrombosis (CVST): A case series and review of the literature
A large proportion of patients with coronavirus disease 19 (COVID‐19) suffer from excessive coagulation activation and coagulopathy which predisposes them to a wide spectrum of thrombotic events including in situ pulmonary thrombosis, deep‐vein thrombosis, and associated pulmonary embolism, as well as arterial thrombotic events. Cerebral venous sinus thrombosis (CVST) have also been reported but in a very small number of cases. This report aims to increase awareness about CVST as a potential neurological thromboembolic complication in patients with coronavirus disease. We report three COVID‐19 patients presenting with CVTS. We also review all previously described cases and present an overview of their demographic, clinical, and diagnostic data. We describe three patients with concomitant coronavirus disease and CVST among 1000 hospitalized COVID‐19 patients (2 males, 1female, and mean age of 37 years). One patient was previously healthy, while the two others had a history of chronic anemia and ulcerative colitis, respectively. CVST symptoms including seizure in two patients and headache in one patient occurred day to weeks after the onset of COVID‐19 symptoms. Three months of anticoagulant therapy was given for all three patients with favorable outcomes. No neurological sequelae and no recurrence occurred within 6 months after hospital discharge. Our search identified 33 cases of COVID‐19 complicated by CVST. The mean age was 45.3 years, there was a slight male predominance (60%), and more than half of cases were diagnosed in previously healthy individuals. All cases of CVT were clinically symptomatic and were observed in patients with a different spectrum of coronavirus disease severity. Headache was the most common complaint, reported by just less than half of patients. There was a high mortality rate (30.3%). CVT is a very rare, but potentially life‐threatening complication in patients with COVID‐19. It's mainly reported in relatively young individuals with no or little comorbid disease and can occur even in patients who do not display severe respiratory symptoms. Atypical clinical presentations may pose a challenge to the early diagnosis and treatment. High suspicion is necessary as early diagnosis and prompt treatment with anticoagulation in all patients with COVID‐19 and CVT could contain the mortality rate and improve neurological outcomes in these patients.
- Open Access
- 3 August 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (8) , e6069
Leser‐Trélat syndrome secondary to non‐small‐cell lung carcinoma
The syndrome of Leser‐Trélat (LT) is a rare paraneoplastic syndrome. However, patients presenting with the sign of Leser‐Trélat should be considered to harbor an occult malignancy or a progressive tumor disease until “proven” otherwise. Herein, we present two cases of non‐small‐cell lung carcinoma associated with LT syndrome.
- 3 August 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (8) , e6069
Open AccessLeser‐Trélat syndrome secondary to non‐small‐cell lung carcinoma
The syndrome of Leser‐Trélat (LT) is a rare paraneoplastic syndrome. However, patients presenting with the sign of Leser‐Trélat should be considered to harbor an occult malignancy or a progressive tumor disease until “proven” otherwise. Herein, we present two cases of non‐small‐cell lung carcinoma associated with LT syndrome.
- Open Access
- 6 April 2022
- Published by Modestum Ltd in Electronic Journal of Medical and Dental Studies
- Vol. 12 (1) , em0097
First Reported Cases of COVID-19-Associated Mucormycosis in Tunisia
COVID-19 infection is associated with several complications such as mucormycosis. We report, to the best of our knowledge, the first published cases of mucormycosis associated with severe COVID-19 infection in Tunisia. The first case was a diabetic, 68-year-old man, who presented a rhino-orbito-cerebral mucromycosis. The second case was a 37-year-old woman with a chronic renal failure hemodialysis stage and liver disease and who presented a rhino-sinuso-orbital mucormycosis. The diagnosis of mucormycosis was retained in both cases seven days after COVID-19 infection. Antifungal treatment was prescriped. Surgical treatment was not possible. Both cases died. We should think about mucormycosis in patients with COVID-19 infection and emergency medical and surgical treatment must be started to reduce mortality.
- 6 April 2022
- Published by Modestum Ltd in Electronic Journal of Medical and Dental Studies
- Vol. 12 (1) , em0097
Open AccessFirst Reported Cases of COVID-19-Associated Mucormycosis in Tunisia
COVID-19 infection is associated with several complications such as mucormycosis. We report, to the best of our knowledge, the first published cases of mucormycosis associated with severe COVID-19 infection in Tunisia. The first case was a diabetic, 68-year-old man, who presented a rhino-orbito-cerebral mucromycosis. The second case was a 37-year-old woman with a chronic renal failure hemodialysis stage and liver disease and who presented a rhino-sinuso-orbital mucormycosis. The diagnosis of mucormycosis was retained in both cases seven days after COVID-19 infection. Antifungal treatment was prescriped. Surgical treatment was not possible. Both cases died. We should think about mucormycosis in patients with COVID-19 infection and emergency medical and surgical treatment must be started to reduce mortality.
- Open Access
- 20 February 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (2) , e05454
Primary thoracic synovial sarcomas: A case report
Primary pulmonary synovial sarcoma (SS) is a rare neoplasm. Its clinicoradiologic attributes are not yet well defined. We report the observation of a patient followed for primary pulmonary synovial sarcoma. We report the radio‐clinical features of this rare tumor.
- 20 February 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (2) , e05454
Open AccessPrimary thoracic synovial sarcomas: A case report
Primary pulmonary synovial sarcoma (SS) is a rare neoplasm. Its clinicoradiologic attributes are not yet well defined. We report the observation of a patient followed for primary pulmonary synovial sarcoma. We report the radio‐clinical features of this rare tumor.
- Open Access
- 17 February 2022
- Published by Wiley in Sleep Disorders
- Vol. 2022, 1-13
Characteristics of Obese Patients with Acute Hypercapnia Respiratory Failure Admitted in the Department of Pneumology: An Observational Study of a North African Population
Background. Acute hypercapnic respiratory failure (AHRF) is a common life-threatening event in patients with obesity hypoventilation syndrome (OHS). Objectives. To study the clinical pattern, noninvasive ventilatory support, as well as the short- and long-term outcomes of patients with OHS admitted in a ward because of AHRF. Methods. We conducted a retrospective cohort study including all adults with OHS , admitted in a 90-bed-ward for AHRF. Results. A total of 44 patients were included. Fifteen (34.1%) and 29 (65.9%) patients were diagnosed with malignant OHS (mOHS) and nonmalignant OHS (non-mOHS), respectively, while 36 (81.8%) had coexisting obstructive sleep apnea hypopnea syndrome (OSAHS). Patients with mOHS had a significantly higher rate of heart failure (100% vs. 31%; ), chronic renal insufficiency (CRI) (73.3% vs. 41.4%; ), and dyslipidemia (66.7% vs. 34.5%; ) than those with non-mOHS. The mean forced vital capacity (FVC) in our patients was of of the predicted value, lower than what is usually reported in stable patients with OHS. At hospital admission, more than two-thirds ( , 77.3%) were misdiagnosed as having asthma exacerbation ( , 4.9.1%), chronic obstructive pulmonary disease (COPD) exacerbation ( , 27.3%) and/or heart failure ( , 65.9%). Acute pulmonary oedema (ACPE) ( , 36.4%) and acute viral bronchitis ( , 27.3%) were the main identified causal factors, while no cause could be determined in 5 (11.4%) patients. Noninvasive positive pressure ventilation (NIPPV) using bilevel positive airway pressure (BIPAP) was very highly effective to treat AHRF, with only 2.27% of patients failing the modality. Median overall duration of ventilation was 9 hours per day (1.3–20) and was significantly longer in patients with mOHS than in those with non-mOHS (10 [6–18] vs. 8 [1.3–20], respectively;
- 17 February 2022
- Published by Wiley in Sleep Disorders
- Vol. 2022, 1-13
Open AccessCharacteristics of Obese Patients with Acute Hypercapnia Respiratory Failure Admitted in the Department of Pneumology: An Observational Study of a North African Population
Background. Acute hypercapnic respiratory failure (AHRF) is a common life-threatening event in patients with obesity hypoventilation syndrome (OHS). Objectives. To study the clinical pattern, noninvasive ventilatory support, as well as the short- and long-term outcomes of patients with OHS admitted in a ward because of AHRF. Methods. We conducted a retrospective cohort study including all adults with OHS , admitted in a 90-bed-ward for AHRF. Results. A total of 44 patients were included. Fifteen (34.1%) and 29 (65.9%) patients were diagnosed with malignant OHS (mOHS) and nonmalignant OHS (non-mOHS), respectively, while 36 (81.8%) had coexisting obstructive sleep apnea hypopnea syndrome (OSAHS). Patients with mOHS had a significantly higher rate of heart failure (100% vs. 31%; ), chronic renal insufficiency (CRI) (73.3% vs. 41.4%; ), and dyslipidemia (66.7% vs. 34.5%; ) than those with non-mOHS. The mean forced vital capacity (FVC) in our patients was of of the predicted value, lower than what is usually reported in stable patients with OHS. At hospital admission, more than two-thirds ( , 77.3%) were misdiagnosed as having asthma exacerbation ( , 4.9.1%), chronic obstructive pulmonary disease (COPD) exacerbation ( , 27.3%) and/or heart failure ( , 65.9%). Acute pulmonary oedema (ACPE) ( , 36.4%) and acute viral bronchitis ( , 27.3%) were the main identified causal factors, while no cause could be determined in 5 (11.4%) patients. Noninvasive positive pressure ventilation (NIPPV) using bilevel positive airway pressure (BIPAP) was very highly effective to treat AHRF, with only 2.27% of patients failing the modality. Median overall duration of ventilation was 9 hours per day (1.3–20) and was significantly longer in patients with mOHS than in those with non-mOHS (10 [6–18] vs. 8 [1.3–20], respectively;
- Open Access
- 2 August 2021
- Published by Wiley
Primary thoracic synovial sarcomas: a case report
Primary pulmonary synovial sarcoma (SS) is a rare neoplasm. Its clinicoradiologic attributes are not yet well defined. We report the observation of a patient followed for primary pulmonary synovial sarcoma. we report the radio-clinical features of this rare tumor.
- 2 August 2021
- Published by Wiley
Open AccessPrimary thoracic synovial sarcomas: a case report
Primary pulmonary synovial sarcoma (SS) is a rare neoplasm. Its clinicoradiologic attributes are not yet well defined. We report the observation of a patient followed for primary pulmonary synovial sarcoma. we report the radio-clinical features of this rare tumor.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Bacteriological and therapeutic features of lung abscess
Background: Primary lung abscess is necrotic cavitary lesion of the lung parenchyma. It is usually caused by anaerobic bacteria or mixed flora. The aim of this study was to describe the epidemiological, clinical, bacteriological and therapeutic features of lung abscess. Methods: This is a retrospective, descriptive study, conducted over a period of 3 years, including patients hospitalized for lung abscess. Results: Our study included 24 patients which mostly were men. The average age was 46.8 years. Sixty percent were smokers. The main patient illness histories were COPD (25%), diabetes (15%), cerebral stroke (5%), epilepsy (5%) and cerebral palsy(5%). The clinical symptomatology was dominated by fever, chest pain and deterioration of the general state. The most common location was the right upper lobe (35%). The bacteriological examination of sputum was negative in 21 patients and positive for pneumococcus (1 case), staphylococcus (1 case) and E. coli (1 case). One case of pseudomonas aeruginosa was isolated by bacteriological examination of the percutaneous drainage fluid. Nine patients (37.5%) were treated with amoxicillin-clavulanic acid and fluoroquinolone and 33.5% of patients received triple therapy included C3G with metronidazeole and fluoroquinolone. The mean duration of treatment was 3.8 weeks. Percutaneous drainage was indicated in 3 patients. Complete resolution of radiological abnormalities was 30 days. Conclusion: The identification of the responsible bacteria in lung abcess remains difficult. Management is based mainly on antibiotics wich is often probabilistic, in some cases associated with physiotherapy, percutaneous scan-guided drainage or rarely surgery.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Bacteriological and therapeutic features of lung abscess
Background: Primary lung abscess is necrotic cavitary lesion of the lung parenchyma. It is usually caused by anaerobic bacteria or mixed flora. The aim of this study was to describe the epidemiological, clinical, bacteriological and therapeutic features of lung abscess. Methods: This is a retrospective, descriptive study, conducted over a period of 3 years, including patients hospitalized for lung abscess. Results: Our study included 24 patients which mostly were men. The average age was 46.8 years. Sixty percent were smokers. The main patient illness histories were COPD (25%), diabetes (15%), cerebral stroke (5%), epilepsy (5%) and cerebral palsy(5%). The clinical symptomatology was dominated by fever, chest pain and deterioration of the general state. The most common location was the right upper lobe (35%). The bacteriological examination of sputum was negative in 21 patients and positive for pneumococcus (1 case), staphylococcus (1 case) and E. coli (1 case). One case of pseudomonas aeruginosa was isolated by bacteriological examination of the percutaneous drainage fluid. Nine patients (37.5%) were treated with amoxicillin-clavulanic acid and fluoroquinolone and 33.5% of patients received triple therapy included C3G with metronidazeole and fluoroquinolone. The mean duration of treatment was 3.8 weeks. Percutaneous drainage was indicated in 3 patients. Complete resolution of radiological abnormalities was 30 days. Conclusion: The identification of the responsible bacteria in lung abcess remains difficult. Management is based mainly on antibiotics wich is often probabilistic, in some cases associated with physiotherapy, percutaneous scan-guided drainage or rarely surgery.